AXQ Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

AXQ Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,241	Closed	-$359K	–	1208
2026 Q1	$359K	Buy	+19,241	New	+$319K	0.05%	534

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AXQ Capital's MLTX Position: Q2 2026 in Review

AXQ Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2026, closing a stake of 19,241 shares — an estimated $359K sold.

AXQ Capital first reported a position in MLTX in Q1 2026 and held it in 1 quarter. The position peaked at $359K in Q1 2026. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

AXQ Capital reported no remaining MoonLake Immunotherapeutics position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 19,241 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $359K.
AXQ Capital first reported a position in MoonLake Immunotherapeutics in Q1 2026 and held it in 1 quarter.
AXQ Capital's MoonLake Immunotherapeutics position peaked at $359K in Q1 2026.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.